← Back to Search

Aspire2B App for Lifestyle Improvement

N/A
Recruiting
Led By Tristin Brisbois, PhD, MBS
Research Sponsored by PepsiCo Global R&D
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up continuous for up to 6 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing Aspire2B, a mobile app that helps people improve their health by tracking their condition and suggesting personalized activities. It targets anyone looking to enhance their wellness. The app uses non-invasive methods to measure health and offers tailored challenges to boost overall well-being.

Who is the study for?
This trial is for people who use smartphones and can read and understand English or Spanish. Participants must be willing to download the Aspire2B app, consent to participate in the study, and agree to the app's Terms of Use.
What is being tested?
The Aspire2B Personalization Pilot Study Program is testing how well a mobile device application works in helping users with nutrition, fitness, and sleep. It's not a randomized study; participants will use the app as part of their daily routine.
What are the potential side effects?
Since this trial involves using an app for lifestyle changes rather than medication, there are no traditional side effects. However, users may experience changes in behavior or lifestyle due to following guidance on nutrition, fitness, or sleep.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~continuous for up to 6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and continuous for up to 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assess the technical characteristics of the app (App proficiency) -Connection
Assess the technical characteristics of the app (App proficiency) -Face scan age
Assess the technical characteristics of the app (App proficiency) -Face scan heart rate
+6 more
Secondary study objectives
Learnings to Inform future versions of the app -Overall engagement
Learnings to inform changes to future versions of the app - Dietary behaviors
Learnings to inform changes to future versions of the app -Lifestyle behaviors
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: SleepExperimental Treatment1 Intervention
Set personalized sleep goals
Group II: NutritionExperimental Treatment1 Intervention
Set personalized nutrition goals
Group III: FitnessExperimental Treatment1 Intervention
Set personalized fitness goals

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for lifestyle-related conditions, such as smoking cessation, often include behavioral interventions, pharmacotherapy, and digital health tools like mobile applications. Behavioral interventions, such as motivational interviewing and cognitive-behavioral therapy (CBT), work by changing the patient's thought patterns and behaviors related to smoking. Pharmacotherapy, including nicotine replacement therapy (NRT) and medications like varenicline, helps reduce withdrawal symptoms and cravings. Mobile health applications, like the Aspire2B app, provide real-time support, personalized feedback, and educational resources, enhancing user engagement and adherence to treatment plans. These mechanisms are crucial for lifestyle patients as they offer accessible, continuous, and tailored support, increasing the likelihood of successful behavior change and long-term health improvements.
A Mobile Just-in-Time Adaptive Intervention for Smoking Cessation: Pilot Randomized Controlled Trial.Text Messaging to Enhance Mindfulness-Based Smoking Cessation Treatment: Program Development Through Qualitative Research.

Find a Location

Who is running the clinical trial?

PepsiCo Global R&DLead Sponsor
92 Previous Clinical Trials
9,879 Total Patients Enrolled
Tristin Brisbois, PhD, MBSPrincipal InvestigatorPepsiCo Global R&D
~818 spots leftby Nov 2025